Abbott Laboratories Research and Development Expenses 2010-2023 | ABT
Abbott Laboratories annual/quarterly research and development expenses history and growth rate from 2010 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Abbott Laboratories research and development expenses for the quarter ending December 31, 2023 were $0.700B, a 3.45% decline year-over-year.
- Abbott Laboratories research and development expenses for the twelve months ending December 31, 2023 were $2.741B, a 5.09% decline year-over-year.
- Abbott Laboratories annual research and development expenses for 2023 were $2.741B, a 5.09% decline from 2022.
- Abbott Laboratories annual research and development expenses for 2022 were $2.888B, a 5.32% increase from 2021.
- Abbott Laboratories annual research and development expenses for 2021 were $2.742B, a 13.31% increase from 2020.
| Abbott Laboratories Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2023 | $2,741 |
| 2022 | $2,888 |
| 2021 | $2,742 |
| 2020 | $2,420 |
| 2019 | $2,440 |
| 2018 | $2,300 |
| 2017 | $2,260 |
| 2016 | $1,447 |
| 2015 | $1,405 |
| 2014 | $1,345 |
| 2013 | $1,371 |
| 2012 | $1,461 |
| 2011 | $1,512 |
| 2010 | $3,724 |
| 2009 | $2,744 |
| Abbott Laboratories Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2023-12-31 | $700 |
| 2023-09-30 | $672 |
| 2023-06-30 | $715 |
| 2023-03-31 | $654 |
| 2022-12-31 | $725 |
| 2022-09-30 | $782 |
| 2022-06-30 | $684 |
| 2022-03-31 | $697 |
| 2021-12-31 | $762 |
| 2021-09-30 | $672 |
| 2021-06-30 | $654 |
| 2021-03-31 | $654 |
| 2020-12-31 | $698 |
| 2020-09-30 | $580 |
| 2020-06-30 | $564 |
| 2020-03-31 | $578 |
| 2019-12-31 | $595 |
| 2019-09-30 | $596 |
| 2019-06-30 | $577 |
| 2019-03-31 | $672 |
| 2018-12-31 | $562 |
| 2018-09-30 | $574 |
| 2018-06-30 | $575 |
| 2018-03-31 | $589 |
| 2017-12-31 | $619 |
| 2017-09-30 | $568 |
| 2017-06-30 | $520 |
| 2017-03-31 | $553 |
| 2016-12-31 | $368 |
| 2016-09-30 | $352 |
| 2016-06-30 | $348 |
| 2016-03-31 | $379 |
| 2015-12-31 | $369 |
| 2015-09-30 | $378 |
| 2015-06-30 | $345 |
| 2015-03-31 | $313 |
| 2014-12-31 | $361 |
| 2014-09-30 | $305 |
| 2014-06-30 | $310 |
| 2014-03-31 | $369 |
| 2013-12-31 | $323 |
| 2013-09-30 | $339 |
| 2013-06-30 | $363 |
| 2013-03-31 | $346 |
| 2012-12-31 | $376 |
| 2012-09-30 | $351 |
| 2012-06-30 | $371 |
| 2012-03-31 | $364 |
| 2011-12-31 | $1,152 |
| 2011-09-30 | $1,010 |
| 2011-06-30 | $1,038 |
| 2011-03-31 | $930 |
| 2010-12-31 | $1,057 |
| 2010-09-30 | $1,079 |
| 2010-06-30 | $858 |
| 2010-03-31 | $730 |
| 2009-12-31 | $747 |
| 2009-09-30 | $676 |
| 2009-06-30 | $670 |
| 2009-03-31 | $651 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $182.557B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $125.439B | 30.04 |
| Medtronic (MDT) | Ireland | $108.284B | 15.33 |
| Boston Scientific (BSX) | United States | $106.687B | 33.98 |
| EssilorLuxottica (ESLOY) | France | $99.794B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.125B | 0.00 |
| Haleon (HLN) | United Kingdom | $37.397B | 27.30 |
| ResMed (RMD) | United States | $31.274B | 29.36 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.862B | 15.88 |
| Terumo (TRUMY) | Japan | $24.701B | 34.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.145B | 18.70 |
| Baxter (BAX) | United States | $18.217B | 12.95 |
| Insulet (PODD) | United States | $12.294B | 64.55 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.929B | 0.00 |
| Demant (WILYY) | Denmark | $10.100B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.650B | 25.02 |
| BellRing Brands (BRBR) | United States | $7.607B | 35.63 |
| Lantheus Holdings (LNTH) | United States | $5.164B | 12.87 |
| Haemonetics (HAE) | United States | $4.736B | 24.22 |
| GN Store Nord (GNNDY) | Denmark | $4.400B | 24.71 |
| Perrigo (PRGO) | Ireland | $4.241B | 12.85 |
| Prestige Consumer Healthcare (PBH) | United States | $3.468B | 16.40 |
| Envista Holdings (NVST) | United States | $3.236B | 13.35 |
| QuidelOrtho (QDEL) | United States | $2.854B | 15.87 |
| TG Therapeutics (TGTX) | United States | $2.646B | 74.43 |
| Neogen (NEOG) | United States | $2.610B | 25.10 |
| Green Thumb Industries (GTBIF) | United States | $2.604B | 51.58 |
| ICU Medical (ICUI) | United States | $2.451B | 21.63 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.230B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $1.843B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.686B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.683B | 49.34 |
| InMode (INMD) | Israel | $1.537B | 8.17 |
| Owens & Minor (OMI) | United States | $1.386B | 12.08 |
| AdaptHealth (AHCO) | United States | $1.288B | 9.59 |
| Warby Parker (WRBY) | United States | $1.233B | 0.00 |
| National Vision Holdings (EYE) | United States | $1.167B | 37.25 |
| AtriCure (ATRC) | United States | $0.985B | 0.00 |
| MacroGenics (MGNX) | United States | $0.917B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.915B | 0.00 |
| Evolus (EOLS) | United States | $0.830B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.813B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.710B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.696B | 14.81 |
| VAREX IMAGING (VREX) | United States | $0.644B | 15.14 |
| Quanterix (QTRX) | United States | $0.631B | 0.00 |
| PetIQ (PETQ) | United States | $0.519B | 16.97 |
| Valneva SE (VALN) | France | $0.504B | 0.00 |
| Jin Medical (ZJYL) | China | $0.494B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.478B | 0.00 |
| Biote (BTMD) | United States | $0.452B | 8.67 |
| Surmodics (SRDX) | United States | $0.450B | 28.20 |
| ZimVie (ZIMV) | United States | $0.419B | 35.77 |
| OraSure Technologies (OSUR) | United States | $0.406B | 12.64 |
| Aurora Cannabis (ACB) | Canada | $0.350B | 0.00 |
| Cerus (CERS) | United States | $0.348B | 0.00 |
| Zynex (ZYXI) | United States | $0.341B | 46.65 |
| Sanara MedTech (SMTI) | United States | $0.283B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.282B | 27.96 |
| TriSalus Life Sciences (TLSI) | United States | $0.258B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.248B | 15.33 |
| Veru (VERU) | United States | $0.209B | 0.00 |
| Omeros (OMER) | United States | $0.205B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.185B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.182B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.173B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.169B | 0.00 |
| InterCure (INCR) | Israel | $0.151B | 25.54 |
| Eagleford Energy (GRUSF) | United States | $0.140B | 70.42 |
| Jushi Holdings (JUSHF) | United States | $0.137B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 22.00 |
| Cellectar Biosciences (CLRB) | United States | $0.115B | 0.00 |
| Fonar (FONR) | United States | $0.111B | 9.54 |
| MariMed (MRMD) | United States | $0.109B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.101B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 0.00 |
| Brainsway (BWAY) | Israel | $0.095B | 0.00 |
| Chimerix (CMRX) | United States | $0.087B | 0.00 |
| Safety Shot (SHOT) | United States | $0.065B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.062B | 4.03 |
| Zevia PBC (ZVIA) | United States | $0.061B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.047B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.047B | 0.00 |
| Apyx Medical (APYX) | United States | $0.047B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Bright Green (BGXX) | United States | $0.041B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.42 |
| Exagen (XGN) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Agape ATP (ATPC) | $0.018B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.016B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.010B | 73.73 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |